phase III trial

(redirected from phase 3 trial)
Also found in: Dictionary, Thesaurus, Legal, Encyclopedia.
Related to phase 3 trial: clinical test, Clinical studies

phase III trial

, phase 3 trial
A clinical trial to explore the clinical use of a new drug, esp. relative to other known effective agents (the current standard of care). These trials often include thousands of enrollee patients. By law, all such patients receive real treatment; no placebos are given. But the trial is usually double-blinded, with patients divided randomly into two groups: an experimental group and a control group on standard treatment, with neither patients nor researchers knowing to which group the patient belongs.
See also: trial
References in periodicals archive ?
associate professor of Pediatrics at the University of North Carolina, Chapel Hill, and also one of the clinical trial's investigators, presented new perspectives on the burden of illness among MPS I patients, which were derived from baseline evaluations of the 45 patients enrolled in the Phase 3 trial of Aldurazyme.
Maxim is also conducting the confirming MP-8899-0104 Phase 3 trial (M0104) in the US and EU in 230 patients.
The positive results from the D9901 trial provide some of the most complete information to date on patients with androgen independent prostate cancer, and the significant results in men with a Gleason score of 7 or less formed the basis of our second Phase 3 trial, D9902B, that is currently enrolling patients," said David Urdal, Ph.
A double blind, placebo controlled Phase 3 trial of Provenge is underway at medical centers throughout the United States.
The M0103 trial was based in the United States and all patients in the trial were treated with the combination of Ceplene and interleukin-2 (IL-2) under the same dosing regimen and protocol that was used in the M01 Phase 3 trial.
Ceplene has been tested in six completed clinical trials for melanoma in more than 800 patients, and is currently being tested in a final Phase 3 trial designed to support U.
In December 2002 Dendreon announced plans for a confirmatory, pivotal Phase 3 trial program for Provenge, based upon discussions with and input from the FDA.
Point is currently studying its lead product candidate, talabostat, in two Phase 3 trials in non-small cell lung cancer.
These studies support Point Therapeutics' clinical program, which includes two Phase 3 trials in metastatic non-small cell lung cancer and Phase 2 trials in advanced CLL, metastatic melanoma and metastatic pancreatic cancer.